Αποτελέσματα Αναζήτησης
11 Δεκ 2021 · The ZUMA-7 trial showed a significant improvement in efficacy with axi-cel therapy, as compared with second-line standard care, in patients with relapsed or refractory large B-cell lymphoma.
11 Μαΐ 2023 · In phase 2 of ZUMA-1, a single-arm, multicenter, registrational trial, axicabtagene ciloleucel (axi-cel) autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy demonstrated durable responses at 2 years in patients with refractory large B-cell lymphoma (LBCL).
28 Δεκ 2017 · In a phase 1 trial, axicabtagene ciloleucel (axi-cel), an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, showed efficacy in patients with refractory large B-cell lymphoma...
5 Νοε 2021 · Here, we report updated survival findings from the phase 2 portion of ZUMA-1 after 4 years of follow-up, including an evaluation of the association of OS with EFS. Methods: Eligible pts had refractory LBCL (diffuse LBCL, primary mediastinal B cell lymphoma, transformed follicular lymphoma).
5 Ιουν 2023 · Conclusions. At a median follow-up of 47.2 months, axi-cel as second-line treatment for patients with early relapsed or refractory large B-cell lymphoma resulted in significantly longer overall...
ZUMA-1 (NCT02348216) examined the safety and efficacy of axicabtagene ciloleucel (axi-cel), an autologous CD19-directed chimaeric antigen receptor (CAR)-T cell therapy, in refractory large B-cell lymphoma.
4 Ιαν 2024 · ZUMA-1 pivotal cohorts 1 + 2 (N = 101) demonstrated high, durable responses (83% objective response rate [ORR]; 58% complete response [CR] rate), and a manageable safety profile with long-term...
